# MiniMed Group, Inc. (MMED)

> Source: Nexqual · https://nexqual.com/MMED · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, MiniMed Group, Inc. (MMED), nexqual.com/MMED" · informational, not investment advice.

**Price:** USD 18 (+7.08% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 16.81 · day 16.6–18.08 · 52w 10.65–24.43 · market cap $5.06B · NMS

## Key facts
- Analysts: Buy (mean 2.31 on a 1–5 scale) (16 analysts), mean target USD 25 (range 15–30).
- Total return with dividends: 1Y -2.6% vs S&P 500 +18.1%; 5Y -2.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD 0.11, revenue estimate $824M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2026 | FY2026 | FY2026 | TTM |
|---|---|---|---|---|
| Revenue | $2.47B | $2.71B | $3.10B | — |
| Gross profit | $1.44B | $1.53B | $1.68B | — |
| Operating income | -$69.0M | -$146M | -$190M | — |
| Net income | -$112M | -$213M | -$333M | -$309M |
| EPS (diluted) | -$0.44 | -$0.84 | -$1.30 | — |
| Free cash flow | -$107M | -$53.0M | -$420M | — |
| Gross margin | 58.2% | 56.3% | 54.2% | — |
| Operating margin | -2.8% | -5.4% | -6.1% | — |
| Net margin | -4.5% | -7.8% | -10.7% | — |
| Revenue growth | — | +10.0% | +14.3% | — |
| Cash + short-term investments | $54.0M | $11.0M | $298M | — |
Fiscal years end Apr. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jul 31, 2026)
P/B 1.4x · Earnings yield -6.10%

## Analysts
Consensus Buy (mean 2.31 on a 1–5 scale), 16 analysts; mean target USD 25 (low 15, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Jefferies | Initiated | Hold | $22 |
| 2026-10-08 | Mizuho | Target raised | Outperform | $26 → $28 |
| 2026-10-07 | Barclays | Initiated | Equal-Weight | $22 |
| 2026-09-24 | Truist Securities | Initiated | Buy | $29 |
| 2026-09-03 | Morgan Stanley | Target raised | Overweight | $19 → $21 |
| 2026-09-02 | Citigroup | Target raised | Buy | $23 → $26 |
| 2026-09-02 | Evercore ISI Group | Target raised | Outperform | $20 → $27 |
| 2026-09-02 | Wells Fargo | Target raised | Overweight | $22 → $26 |
| 2026-09-02 | UBS | Target raised | Buy | $25 → $28 |
| 2026-09-02 | Mizuho | Target raised | Outperform | $21 → $26 |
| 2026-09-02 | B of A Securities | Target raised | Buy | $24 → $28 |
| 2026-09-01 | BTIG | Target raised | Buy | $25 → $28 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-03-06) | 5Y (from 2026-03-02) |
|---|---|---|
| Total return | -2.6% | -2.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 57.6% | 55.0% |
| Max drawdown | -41.6% (Mar 2026→May 2026) | -41.6% (Mar 2026→May 2026) |

## Peers (Medical Instruments & Supplies)
STVN (Stevanato Group S.p.A.) USD 19.25 -0.05% · MMSI (Merit Medical Systems, Inc.) USD 89.57 +1.62% · TFX (Teleflex Incorporated) USD 128.22 +3.04% · BLCO (Bausch + Lomb Corporation) USD 16.66 +5.38% · ICUI (ICU Medical, Inc.) USD 167.23 +2.45% · NVST (Envista Holdings Corporation) USD 23.5 +3.75%

## More
Full page: https://nexqual.com/MMED · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt